scholarly journals Evaluation of clinical parameters related to methotrexate therapy in lichen planus

2016 ◽  
Vol 6 (2) ◽  
pp. 90
Author(s):  
Samaresh Chandra Hazra ◽  
Agha Masood Choudhury ◽  
Lubna Khondker ◽  
Md. Shirajul Islam Khan ◽  
Muhammad Munir Rashid
Keyword(s):  
Clinical Trial ◽  
Lichen Planus ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
Clinical Parameters ◽  
Morning Dose ◽  
Group A ◽  
Group B ◽  
And Control

<p><strong>Background:</strong> For better management of lichen planus a clinical trial of oral methotrexate is necessary in ow· country. Objective: The objective of this study is to evaluate efficacy and safety ofmethotrexate therapy in the treatment of lichen planus.</p><p><strong>Methods:</strong> It was a prospective randomized controlled clinical trial conducted in the department of Dermatology and Venereology, BSMMU, Dhaka, from January 2009 to December 2010. Forty four patients of lichen planus were included in the study. Cases (group-A, n=23) were treated with methotrexate (10 mg) single morning dose and control (group-B, n=21) were treated with mini pulse betamethasone (5mg) single morning dose on 2 consecutive days during the period of 12 weeks. <strong></strong></p><p><strong>Results:</strong> Clinical parameters were measured by follow up clinical examination. Morphological lesion of lichen planus improved 95. 7% in group-A and only 28.6% improved in group-B. At the end of study 82.6% bad no complaints of itching in group-A and 100% had no complaints of itching in group-B. 16(69.6%) patients in group-A were completely cured clinically but 10(47.6%) in group-B. Anemia 3(14.2%) and edema 12(57.1 %) developed in group-B but none in group-A. In group-B, dyspepsia 15(71.4%), acne 10(47.6%),mooning face 8(38.1%), striae 8(38.1%) and hyper­trichosis 4(19.0%) developed but none in group-A lntermittenr diarrhoea, headache, nausea and fatigue complained in both groups of patients but the percentage of complaints was higher amog group-8 compared to group-A. Menstrual abnormality developed in group-B 5(71.4%) but none in group-A.</p><p><strong>Conclusion:</strong> The overall adverse effects were less in group-A than group-B. Therefore, methotrexate can be used as an alternative safer option for the treatment of lichen planus.</p>

scholarly journals Efficacy of Locally Administered 1.2% Rosuvastatin Gel in Patients with Periodontitis: A Randomized Placebo Controlled Clinical Trial

2019 ◽  
Vol 13 (01) ◽  
pp. 029-035 ◽  
Author(s):  
Debopriya Chatterjee ◽  
Anjali Kapoor ◽  
Sharmistha Vijay ◽  
Geetika Sobti ◽  
Dheeraj Kara ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Phase 1 ◽  
Colony Count ◽  
Controlled Clinical Trial ◽  
Clinical Parameters ◽  
Pharmacological Agents ◽  
Intergroup Comparison ◽  
Significant Difference ◽  
Group A ◽  
Group B

Abstract Objective Periodontitis initiation and progression are a result of host immune inflammatory response to oral pathogens. Several pharmacological agents are being delivered locally, to improve periodontal health. Hence, the present randomized placebo controlled clinical trial is designed to check the clinical and antimicrobial efficacy of locally delivered 1.2% rosuvastatin (RSV) in intrabony defects (IBD) in periodontitis patients. Materials and Methods One-hundred patients were randomly allotted into two treatment groups: group A received 1. 2% RSV gel, scaling and root debridement and group B received placebo gel, scaling and root debridement. Clinical parameters, including modified sulcus bleeding index (mSBI), probing depth (PD), clinical attachment level (CAL), and plaque index (PI), were recorded at baseline before phase 1 and after 6 months. Radiographic assessment of IBD was done by cone beam computed tomography at baseline and after 6 months. Anaerobic colony count was done at baseline and after 180 days. Results On intragroup comparison, there is a significant improvement in periodontal parameters in both the groups. On intergroup comparison, there is significant gain in CAL in group A than group B (p = 0.04). There is significant decrease in PD in group A, compared to group B. There is significant bone fill in group A (p = 0.034), compared to group B. With respect to mSBI, PI, and anaerobic colony count, there is no significant difference between the two groups after 6 months. No adverse effect was noticed in any subjects. Conclusion The author concludes that 1.2% RSV gel when delivered locally into IBD improved periodontal clinical parameters such as PD and CAL and showed significant bone fill.

scholarly journals Ultrafiltration (UF) Effectiveness on intradialytic hypertension (IDH) in chronic hemodialysed patients in a nephrology unit in Dakar: UF-IDH clinical trial

2021 ◽  
pp. 25
Author(s):  
Keyword(s):  
Clinical Trial ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Control Group ◽  
Cross Sectional ◽  
Before And After ◽  
Group A ◽  
Group B ◽  
And Control ◽  
Interventional Group

Introduction Progressive ultrafiltration (UF) could improve IDH. The aim of this work was to evaluate the effectiveness of progressive UF in the management of IDH. Methods This randomized clinical trial in two groups: interventional group A (UF, n = 12) and control group B (n = 12), was conducted in chronic hemodialysis patients with IDH. A first phase of cross-sectional collection of BP before and after dialysis, during 2 weeks, made it possible to obtain this cohort of 24 patients. A progressive decrease in basal weight of 0.25 kg per session as a function of hemodynamic tolerance was achieved in group A. The primary endpoint, the proportion of patients with disappearance of IDH, was assessed at baseline end of the 4th and 8th week. Results At the 4th week, the IDH disappeared in 83.3% and 41.7% of the patients of the group A and B respectively with a hazard ratio (HR) at 0.29; IC 95 = [0.14-0.59]; p = 0.035. At the 8th week, the IDH was missing in 72.7% and 66.7% of the patients of the group A and B respectively with a HR at 0.76; IC 95 = [0.58-1.00]; p = 0.75. In addition, the decrease in basal weight was associated with the occurrence of side effects (p = 0.0001) with a HR of 5 [1.45-7.27]. UF discontinuation was required in 4 patients in group A (36.4%). Conclusion Progressive UF was associated with a significant reduction in the prevalence of IDH in our patients at week 4.

scholarly journals Comparative Study on the Application of Mesenchymal Stromal Cells Combined with Tricalcium Phosphate Scaffold into Femoral Bone Defects

2018 ◽  
Vol 27 (10) ◽  
pp. 1459-1468 ◽  
Author(s):  
Pavel Šponer ◽  
Tomáš Kučera ◽  
Jindra Brtková ◽  
Karel Urban ◽  
Zuzana Kočí ◽  
...  
Keyword(s):  
Stromal Cells ◽  
Tricalcium Phosphate ◽  
Bone Defects ◽  
Control Group ◽  
Graft Material ◽  
Synthetic Graft ◽  
Group A ◽  
Group B ◽  
And Control

This prospective study sought to evaluate the healing quality of implanted ultraporous β-tricalcium phosphate sown with expanded autologous mesenchymal stromal cells (MSCs) into femoral defects during revision hip arthroplasty. A total of 37 osseous defects in 37 patients were treated and evaluated concerning bone regeneration. Nineteen subjects received β-tricalcium phosphate graft material serving as a carrier of expanded autologous MSCs (the trial group A), nine subjects received β-tricalcium phosphate graft material only (the study group B) and nine subjects received cancellous allografts only (the control group C). Clinical and radiographic evaluations were scheduled at 6 weeks, 3, 6, and 12 months post-operatively, and performed at the most recent visit as well. All observed complications were recorded during follow-up to assess the use of an ultraporous β-tricalcium phosphate synthetic graft material combined with expanded MSCs in bone defect repair. The resulting data from participants with accomplished follow-up were processed and statistically evaluated with a Freeman–Halton modification of the Fischer’s exact test, a P < 0.05 value was considered to be significant. Whereas no significant difference was observed between the trial group A with β-tricalcium phosphate synthetic graft material serving as a carrier of expanded autologous MSCs and control group C with cancellous impaction allografting in terms of the bone defect healing, significant differences were documented between the study group B with β-tricalcium phosphate graft material only and control group C. Regarding adverse effects, six serious events were recorded during the clinical trial with no causal relationship to the cell product. β-tricalcium phosphate synthetic graft material serving as a carrier of expanded autologous MSCs appears safe and promotes the healing of bone defects in a jeopardized and/or impaired microenvironment. This clinical trial was registered at the EU Clinical Trials Register before patient recruitment (Registration number: EudraCT number 2012-005599-33; Date of registration: 2013-02-04).

scholarly journals Platelet-Rich Plasma versus Corticosteroid Intra-Articular Injections for the Treatment of Trapeziometacarpal Arthritis: A Prospective Randomized Controlled Clinical Trial

Cartilage ◽  
2018 ◽  
Vol 12 (1) ◽  
pp. 51-61 ◽  
Author(s):  
Michael-Alexander Malahias ◽  
Leonidas Roumeliotis ◽  
Vasileios S. Nikolaou ◽  
Efstathios Chronopoulos ◽  
Ioannis Sourlas ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Platelet Rich Plasma ◽  
Symptomatic Relief ◽  
Controlled Clinical Trial ◽  
Dash Score ◽  
Ultrasound Guided ◽  
Radiographic Osteoarthritis ◽  
Group A ◽  
Group B

Various systematic reviews have recently shown that intra-articular platelet-rich plasma (IA-PRP) can lead to symptomatic relief of knee osteoarthritis for up to 12 months. There exist limited data on its use in small joints, such as the trapeziometacarpal joint (TMJ) or carpometacarpal joint (CMCJ) of the thumb. A prospective, randomized, blind, controlled, clinical trial of 33 patients with clinical and radiographic osteoarthritis of the TMJ (grades: I-III according to the Eaton and Littler classification) was conducted. Group A patients (16 patients) received 2 ultrasound-guided IA-PRP injections, while group B patients (17 patients) received 2 ultrasound-guided intra-articular methylprednisolone and lidocaine injections at a 2-week interval. Patients were evaluated prior to and at 3 and 12 months after the second injection using the visual analogue scale (VAS) 100/100, shortened Disabilities of the Arm, Shoulder, and Hand Questionnaire (Q-DASH), and patient’s subjective satisfaction. No significant differences between the baseline clinical and demographic characteristics of the 2 groups were identified. After 12 months’ follow-up, the IA-PRP treatment has yielded significantly better results in comparison with the corticosteroids, in terms of VAS score ( P = 0.015), Q-DASH score ( P = 0.025), and patients’ satisfaction ( P = 0.002). Corticosteroids offer short-term relief of symptoms, but IA-PRP might achieve a lasting effect of up to 12 months in the treatment of early to moderate symptomatic TMJ arthritis.

scholarly journals Comparison of Analgesic Effects of UST with NSAIDs and without NSAIDs in Patients with De Quervain’s Disease

2019 ◽  
Vol 32 (1) ◽  
pp. 25-32
Author(s):  
ABM Zafar Sadeque ◽  
AKM Salek ◽  
Md Tariqul Islam Khan ◽  
Badrunnesa Ahmed ◽  
Hasan Habibur Rahman ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Pain Treatment ◽  
Control Group ◽  
De Quervain’S Disease ◽  
Significant Difference ◽  
Group A ◽  
Anti Inflammatory ◽  
Group B

Background: De Quervain's disease has been described as an entrapment of the extensor pollicis brevis and abductor pollicis longus tendons in the first dorsal compartment of the wrist is a common cause of wrist and hand pain Treatment of the disease consists of pharmacological & non-pharmacological. The non-pharmacological includes immobilization, therapeutic heat and cold, electrical nerve stimulator, thumb stabilizer splint, postural correction at work and the adjustment of tools and equipment. This randomized clinical trial was performed to find out the effects of UST with NSAIDs and without NSAIDs in the patients of De Quervain’s disease. Methods: This randomized clinical trial was performed in the Department of Physical Medicine and Rehabilitation, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, over a period of six months. Group A-experimental or interventional group and group B-control group by randomization with the help of lottery. Experimental group was managed by activities of daily living (ADLs) instructions, ultrasound therapy (UST) with non-steroidal anti-inflammatory agents (NSAIDs gel), along with thumb spica splint. Control group B received previous management except non-steroidal anti-inflammatory agents (NSAIDs gel). All patients received therapeutic ultrasound in a same dosage (1 watt/ cm 2/min) for 8 minutes. An evaluation was made at initial visit and two weeks interval for 6 weeks. So, there were three follow up visits and these evaluations were performed by the same investigator. In each visit, measurement of pain intensity and disability level were performed by using visual analogue scale (VAS), Tenderness Index and Patient rated wrist evaluation (PRWE) respectively. All results was recorded systematically. A post intervention result was compared with baseline result by SPSS-20 Results: Out of 60 total patients 60(100%) had Finkelstein test positive. Significant difference between Group A and Group B was found at week 4 and Week 6 follow up (P<0.05) whereas other early follow up was non-significant in VAS analysis (p>0.05). Significant difference between Group A and Group B was found at week 4 and week 6 follow up (P<0.05) regarding change of tenderness and PRWE. Conclusion: Regarding treatment of De Quervain's disease, present study shown that UST with NSAIDs gel reduces the morbidity and relief of pain of patients when in comparison to other conventional treatment. TAJ 2019; 32(1): 25-32

scholarly journals A COMPARATIVE CLINICAL STUDY OF KADALI KSHAR PRATISARAN AND INJ. SETROL IN THE MANAGEMENT OF ABHYANTAR ARSHA W.S.R. TO INTERNAL HAEMORRHOIDS.

2019 ◽  
pp. 1-3
Author(s):  
Amit Paliwal
Keyword(s):  
Clinical Study ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
Randomized Controlled ◽  
Detailed Explanation ◽  
Comparative Clinical Study ◽  
Group A ◽  
Group B ◽  
And Control

There is a very peculiar role of “Kshar Karma” (an Anushastra), in the management of Arsha, as described by Sushrutacharya.Acharyas have mentioned Kadali as suitable for the Kshara formulation. Patients suffering from AbhyantaraArsha are subjected to KadaliPratisaraneeyaKshar and efficacy ofKadaliKsharPratisaran and inj. Setrol is compared in the management of AbhyantarArsha. In Clinical study an Open randomized controlled clinical trial is conducted of trial group A and control group B for 30 patients in each group.In observations a detailed explanation is given aboutdistribution of patients according to age, sex, occupation.The results of the study are analyzed statistically compared and are presented in tables and graphs form. By highlighting the outcome of the study along with limitations and scope of further improvement it is concluded that KadaliKsharpratisarana gives potent effects in AbhyantarArsha

Outcome of lymph node tuberculosis management with conventional treatment with and without prednisolone

2021 ◽  
pp. 004947552098474
Author(s):  
Arjuman Sharmin ◽  
Ali Hossain ◽  
Nazmul Islam ◽  
Zakir H Sarker ◽  
Sheikh S Hossain ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Lymph Node ◽  
Complete Resolution ◽  
Conventional Treatment ◽  
Symptomatic Improvement ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
Open Label ◽  
Lymph Node Tuberculosis ◽  
And Control

The outcome of lymph node tuberculosis (LNTB) management with conventional anti-tubercular treatment alone is unsatisfactory. We conducted a randomised open-label controlled clinical trial in the Department of Respiratory Medicine in Government Institute of Dhaka, Bangladesh from April 2017 to March 2019. Compared with controls, 54 patients of LNTB received category 1 anti-tubercular treatment with additional prednisolone after randomisation. Complete resolution in 21/54 (75%) and 7 (26.9%), symptomatic improvement in 26 (92.9%) and 22 (84.6%) and complications in 11 (39.28%) and 16 (61.53%) were observed in the treatment and control group, respectively. Thus, we recommend the use of steroids in this setting.

Resorbable Collagen Barrier Impeding the Extrusion of Obturating Material in Primary Molars Undergoing Resorption – A Randomized Clinical Trial

2021 ◽  
Vol 45 (5) ◽  
pp. 312-316
Author(s):  
Mishra Neha Sanjeev ◽  
Harsimran Kaur ◽  
Sandeep Singh Mayall ◽  
Rishika ◽  
Ramakrishna Yeluri
Keyword(s):  
Test Group ◽  
Primary Molars ◽  
Control Group ◽  
Chi Square ◽  
Significance Level ◽  
Significant Difference ◽  
Chi Square Test ◽  
Group A ◽  
Group B ◽  
And Control

Objective: To evaluate the effectiveness of placing a resorbable collagen barrier in impeding the extrusion of obturation material in primary molars undergoing resorption. Study design: All the 94 canals in 47 mandibular molars were allocated to 2 groups- Group ‘A’- 47 canals with collagen barrier (Test group) and Group ‘B’- 47 canals without collagen barrier (Control group) based on randomization protocol. Pulpectomy was performed and obturation of both test and control canals were radiographically assessed. Pearson’s chi – square test was applied to analyze the results. The significance level was predetermined at p &lt; 0.05. Results: Among the test group, 93.6% of the canals showed no extrusion while, 6.4% showed visible extrusion of the material outside the apex. In the control group, 83% showed no extrusion whereas 17% of the canals showed visible extrusion outside the apex. But no significant difference was noted (p&gt;0.05). Conclusion: The placement of resorbable collagen barrier in the apical third of the canal prevented the extrusion of obturating material beyond the apex in resorbing primary molars.

scholarly journals Adverse outcome of methotrexate and mini pulse betamethasone in the treatment of lichen planus

2013 ◽  
Vol 39 (1) ◽  
pp. 22-27 ◽  
Author(s):  
SC Hazra ◽  
AM Choudhury ◽  
ATM Asaduzzaman ◽  
HK Paul
Keyword(s):  
Adverse Effects ◽  
Lichen Planus ◽  
Adverse Outcome ◽  
Adverse Outcomes ◽  
Haematological Parameter ◽  
Morning Dose ◽  
Group A ◽  
Laboratory Investigations ◽  
Group B ◽  
Medical University

The objectives of this study were to compare the adverse outcome of methotrexate and mini pulse betamethasone therapy in the treatment of lichen planus. It was a clinical trial conducted in the department of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University, Dhaka, from January 2009 to December 2010. Forty four patients of lichen planus were included in the study. Patients in Group-A, (n=23) were treated with methotrexate (10 mg) single morning dose and group-B (n=21) were treated with mini pulse betamethasone (5mg) single morning dose on 2 consecutive days during the period of 12 weeks. Adverse outcomes were measured by clinical examination and laboratory investigations during follow up visits. Anemia 3(14.2%) and edema 12(57.1%) developed in group-B but none in group-A. In group-B, dyspepsia 15(71.4%), acne 10(47.6%), mooning face 8(38.1%), striae 8(38.1%) and hypertrichosis 4(19.0%) developed but none in group-A. Intermittent diarrhoea, headache, nausea and fatigue complained in both groups of patients but the percentage of complaints was higher amog group-B compared to group-A. Menstrual abnormality developed in group-B 5(71.4%) but none in group-A. Laboratory investigations showed abnormality in platelet count and SGPT in group-A but none in group-B. The adverse effects of methotrexate on haematological parameter and liver functions were mild and could be prevented by reducing the dose but the adverse effects of betamethasone were unavoidable. The overall adverse effects were less in group-A than group-B. Therefore, methotrexate can be used as an alternative safer option for the treatment of lichen planus. DOI: http://dx.doi.org/10.3329/bmrcb.v39i1.15806 Bangladesh Med Res Counc Bull 2013; 39: 22-27

scholarly journals Effect of Probiotics on Allergic Rhinitis: A Randomized, Controlled, Clinical Trial

2020 ◽  
Vol 9 ◽  
pp. 1918 ◽  
Author(s):  
Mahnaz Sadeghi-Shabestari ◽  
Yalda Jabbari Moghaddam ◽  
Hasan Rezapoor ◽  
Mojataba Sohrabpour
Keyword(s):  
Clinical Trial ◽  
Allergic Rhinitis ◽  
Standard Therapy ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
P Value ◽  
Nasal Discharge ◽  
Oral Corticosteroids ◽  
And Control

Background: Allergic rhinitis (AR) is one of the most common diseases in the world and affects about 10-50% of the general population. Probiotics are live microorganisms that help the normal state of the intestine, and if prescribed correctly, they can stimulate the mucosal immune system to prevent inflammatory symptoms of allergy and atopy. The present study aims to investigate the role of probiotics in the treatment of AR when added to standard therapy as adjuvant agents. Materials and Methods: In this clinical trial study, 28 patients older than 15 years with AR randomly divided into probiotics and control groups. The probiotics group received standard therapy for AR accompanied by probiotic capsules every 12 hours for eight weeks, whereas the control group received standard therapy for AR with placebo capsules as the same protocol. Data were analyzed using SPSS Version 23 (IBM Corporation, Armonk, NY, USA) and, the P-value less than 0.05 was considered statistically significant. Results: In the probiotics group, 14.3% of patients had sneezing at the baseline, which significantly decreased to 4.6% (P<0.01). Also, the necessity for nasal and oral corticosteroids after treatment with probiotics in the probiotics group was less than the control group (P<0.01). Although cough, nasal discharge, conchae hypertrophy, and night sleep disorders reduced after treatment with probiotics, this reduction was not statistically significant between the two groups. Conclusion: Based on the results of this clinical trial, the use of probiotics had no significant effect on the outcome of patients with AR. [GMJ.2020;9:e1918] 

Sign in / Sign up

Export Citation Format

Share Document